# Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

> **NCT03817125** · PHASE1 · COMPLETED · sponsor: **Parker Institute for Cancer Immunotherapy** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Placebo for antibiotic
- **DRUG:** Vancomycin pretreatment
- **DRUG:** Nivolumab
- **DRUG:** Matching Placebo for SER-401
- **DRUG:** SER-401

## Key facts

- **NCT ID:** NCT03817125
- **Lead sponsor:** Parker Institute for Cancer Immunotherapy
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-28
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817125, "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03817125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*